Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Praxis Precision Medicines, Inc.PRAX · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required |
| Reliability | 0.91 AUCfailure model, filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| Peer failure rate | 1.01% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $591M to $2.67B assetstotal assets $937.9M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | dilution, thin data, degenerate inputsnot computable: fortress balance sheet |
| Inputs computable | 6 of 14 |
| Graded from | filings received through Feb 19, 2026232 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $263.402026-10-08; market equity $7.4B; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Feb 19, 2026; the document on sec.gov.
We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 51.9 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (7.6%) | [1,5-7] | (6.6%) | 51.9 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 15.1 | |||||||
| Twelve-month failure probability | 0.04% | 0.07% | 23.1 | 248 | 2026-06-30 | ||
| Altman Z double-prime | 12.98 | [1,8-13] | (0.31) | 6.4 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| one or more required annual facts are missing | |||||||
| Current ratio | 10.22x | [8-9] | 2.96x | 16.0 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 37.2 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 3 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Asset growth, three years | 101.2% | [1,7,14-15] | 2.1% | 2.3 | 704 | 2025-12-31 | |
| Net share issuance, one year | 38.1% | [3-4] | 2.5% | 72.0 | 634 | 2026-02-16 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 560.9% | 8.0% | 99 | hotter than 99 of 100 peers |
| Distance from 52-week high | (31.8%) | (31.4%) | 49 | closer to its high than 49 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (3.4%) | (1.0%) | 44 | pricier than 56 of 100 peers |
| Book value to price | 0.18 | 0.28 | 38 | pricier than 62 of 100 peers |
| Sales to price | 0.00 | 0.31 | 0 | pricier than 100 of 100 peers |
| Composite equity issuance, five years | 238.5% | 20.3% | 93 | more equity-funded than 93 of 100 peers |
| Relative strength against the sector, log excess return | 1.68 | (0.14) | 99 | ahead of 99 of 100 peers |
Inputs: market equity $7.4B; EBIT -$326.2M; free cash flow -$249.1M; book equity $1.3B; sales $0; cash $474.8M[16].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (62.8%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$249.1M | ✗ fail[6] |
| Return on assets improved | 145.1 pts | ✓ pass[5,7,14,17] |
| Operating cash flow exceeds net income | $54.2M | ✓ pass[5-6] |
| Long-term leverage fell | n/a[1,7,14] | |
| Current ratio improved | (54.8 pts) | ✗ fail[8-9,18-19] |
| No new shares issued | 38.1% | ✗ fail[3-4] |
| Gross margin improved | n/a | |
| Asset turnover improved | (9.7 pts) | ✗ fail[2,7,14,20] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $474.8M[21] |
| Operating cash flow, four quarters | -$305.1M[6,21-25] |
| Months of runway | 18.7 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 64 |
| 10-Q received Aug 6, 2026 | |
| Median daily dollar volume | $118.6M |
| 63 sessions | |
| Days since newest grade input | 232 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $937.9M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:Revenues | $0 | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 3 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 27,850,833 | 2026-02-16 | 2026-02-19 | 10-K | filing · viewer · series |
| 4 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 20,163,250 | 2025-02-26 | 2025-02-28 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$303.3M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$249.1M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $483.1M | 2024-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 8 | current assets | us-gaap:AssetsCurrent | $610.9M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $59.8M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.1B | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$326.2M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 12 | book equity | us-gaap:StockholdersEquity | $878.1M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 13 | liabilities | us-gaap:Liabilities | $59.8M | 2025-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 14 | assets | us-gaap:Assets | $87.9M | 2023-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $115.1M | 2022-12-31 | 2024-03-05 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 27,919,988 | 2026-07-31 | 2026-08-06 | 10-Q | filing · viewer · series |
| 17 | net income | us-gaap:NetIncomeLoss | -$182.8M | 2024-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 18 | current assets | us-gaap:AssetsCurrent | $404.4M | 2024-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 19 | current liabilities | us-gaap:LiabilitiesCurrent | $37.5M | 2024-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 20 | revenue | us-gaap:Revenues | $8.6M | 2024-12-31 | 2026-02-19 | 10-K | filing · viewer · series |
| 21 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $474.8M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$163.7M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$86.2M | 2026-03-31 | 2026-05-07 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$172.7M | 2025-09-30 | 2025-11-05 | 10-Q | filing · viewer · series |
| 25 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$107.7M | 2025-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.